NICE recommendations for mavacamten▼

NICE recommends mavacamten as an option for treating symptomatic obstructive HCM in adults who have a NYHA class of II to III only if: it is used as an add-on to individually optimised standard of care that includes beta blockers, non-dihydropyridine calcium channel blockers or disopyramide, unless these are contraindicated; and BMS provides mavacamten according to the commercial agreement.¹

Mavacamten is the first licensed treatment for symptomatic obstructive HCM
that targets the underlying pathophysiology of the condition rather than just
its symptoms¹

BB, beta blocker; BMS, Bristol Myers Squibb; CCB, calcium channel blocker; HCM, hypertrophic cardiomyopathy; NICE, National Institute for Health and Care Excellence;
NYHA, New York Heart Association; SoC, standard of care.

Reference

NICE. Available at: https://www.nice.org.uk/guidance/ta913/resources/mavacamten-for-treating-symptomatic-obstructive-hypertrophic-cardiomyopathy-pdf-82615485457861. Date accessed: March 2026.

3500-GB-2600053 | March 2026